Jaguar health & synworld technologies mutually agree to terminate license and commercialization agreement for canalevia for treatment of diarrhea in dogs in china given jaguar's 2023 focus on human drug development

Tao wang, synworld's general manager and a long-term shareholder of restricted jaguar stock, fully aligned on termination decision san francisco, ca / accesswire / february 1, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") and synworld technologies corporation (synworld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement (the "canalevia agreement") executed in june 2022 for the treatment of diarrhea in dogs in the china market with jaguar's canalevia® (crofelemer delayed-release tablets) prescription drug product effective january 31, 2023. "given jaguar's sharp strategic focus in 2023 on human drug development - specifically on our phase 3 pivotal ontarget trial of crofelemer for our core follow-on indication of prophylaxis of cancer therapy-related diarrhea (ctd) and our crofelemer development efforts for the rare disease indications of short bowel syndrome (sbs) and congenital diarrheal disorders (cdd) - we and synworld have agreed that it makes sense to terminate the canalevia agreement at this time," said lisa conte, jaguar's founder, president, and ceo.
JAGX Ratings Summary
JAGX Quant Ranking